GLP-1R agonists increase GLP-1 activity while protecting the heart from hypertension, myocardial hypertrophy, and myocardial fibrosis, suggesting that GLP-1R agonist therapy is not limited to diabetes and obesity (6, 7). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.